Payment overview · 2025
General Payments
$1,919.17
103 reported records · 21 companies
Healthcare provider profile · identity verified
Dalya S Shamon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STERLING HEIGHTS, MI · NPI 1164657805
Verified facts
What the public records show
CMS Open Payments records show Dalya S Shamon, M.D. received $1,919.17 in general payments during 2025 across 103 reported records.
UCB, Inc. accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $228.07 | 11.9% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.32 | 10.5% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.76 | 10.0% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $161.08 | 8.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.67 | 8.3% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$150.59 | 7.8% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.63 | 7.6% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $141.34 | 7.4% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $107.52 | 5.6% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $92.14 | 4.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.65 | 3.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.96 | 2.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.06 | 2.2% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.28 | 1.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.16 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.93 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.43 | 1.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.43 | 1.0% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $18.40 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.42 | 0.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.33 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,919.17 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $159.62 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.67 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $154.82 | 10 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $150.59 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $141.34 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.31 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.31 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $116.85 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $107.52 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $102.15 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.22 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $92.14 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.61 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.61 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.65 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $47.75 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $44.23 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.06 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| DUOPA Normalized: duopa |
Drug | ABBVIE INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 228 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 499 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 306 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
306 | 41 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
499 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
131 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
228 | 29 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 151 |
| Metformin Hcl | Metformin Hcl | 719 | 98 |
| Jardiance | Empagliflozin | 499 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 84 |
| Losartan Potassium | Losartan Potassium | 446 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 416 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 405 | 49 |
| Omeprazole | Omeprazole | 391 | 77 |
| Lisinopril | Lisinopril | 351 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 44 |
| Linzess | Linaclotide | 306 | 41 |
| Carvedilol | Carvedilol | 255 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 42 |
| Gemtesa | Vibegron | 228 | 29 |
| Famotidine | Famotidine | 203 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 41 |
| Simvastatin | Simvastatin | 177 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 21 |
| Ketoconazole | Ketoconazole | 157 | 22 |
| Gabapentin | Gabapentin | 152 | 29 |
| Ezetimibe | Ezetimibe | 148 | 25 |
| Atenolol | Atenolol | 145 | 24 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 144 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 22 |
| Baclofen | Baclofen | 140 | 20 |
| Eliquis | Apixaban | 138 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 123 | 29 |
| Hydrocortisone | Hydrocortisone | 118 | 25 |
| Tradjenta | Linagliptin | 118 | 20 |
| Ozempic | Semaglutide | 117 | 20 |
| Farxiga | Dapagliflozin Propanediol | 112 | 17 |
| Enalapril Maleate | Enalapril Maleate | 107 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 48 |
| Meloxicam | Meloxicam | 101 | 17 |
| Tramadol Hcl | Tramadol Hcl | 97 | 20 |
| Ibuprofen | Ibuprofen | 93 | 27 |
| Nystatin | Nystatin | 93 | 24 |
| Alendronate Sodium | Alendronate Sodium | 90 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 29 |
| Prednisone | Prednisone | 83 | 46 |
| Vascepa | Icosapent Ethyl | 79 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 78 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 14 |
| Sertraline Hcl | Sertraline Hcl | 74 | 12 |
| Furosemide | Furosemide | 73 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 71 | 25 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Amoxicillin | Amoxicillin | 68 | 47 |
| Azithromycin | Azithromycin | 66 | 42 |
| Mounjaro | Tirzepatide | 64 | 12 |
| Lidocaine | Lidocaine | 63 | 14 |
| Mirtazapine | Mirtazapine | 62 | suppressed |
| Celecoxib | Celecoxib | 61 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 61 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 20 |
| Nitroglycerin | Nitroglycerin | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Allopurinol | Allopurinol | 52 | 11 |
| Trazodone Hcl | Trazodone Hcl | 52 | 14 |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 50 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Fenofibrate | Fenofibrate,micronized | 46 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Procto-Med Hc | Hydrocortisone | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 12 |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 17 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 12 |
| Valsartan | Valsartan | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 21 |
| Promethazine Hcl | Promethazine Hcl | 30 | 27 |
| Torsemide | Torsemide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Prolia | Denosumab | 26 | 18 |
| Finasteride | Finasteride | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Loperamide | Loperamide Hcl | 23 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 22 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Metronidazole | Metronidazole | 18 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Restasis Multidose | Cyclosporine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,919.17 · 103 records | UCB, Inc. | AIRSUPRA, Briviact, Cologuard Collection Kit, DUOPA, ELIQUIS, EPIDIOLEX, EVENITY, Fintepla, GEMTESA, Grastek, HYQVIA, IBSRELA, INGREZZA, JARDIANCE, LINZESS, Motpoly XR, NURTEC ODT, Nayzilam, OTEZLA, Odactra, Ozempic, QULIPTA, REPATHA, REXULTI, Ragwitek, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VYALEV, VYEPTI, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error